Cargando…
Fumarate hydratase-deficient renal cell carcinoma in extended remission with bevacizumab and erlotinib
Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant syndrome associated with fumarate hydratase (FH) gene mutation leading to defective DNA double-strand break repair mechanism. Although these tumours have an aggressive presentation, they respond well to targeted ther...
Autores principales: | Tomar, Shubham, Kashyap, Lakhan, Kapoor, Akhil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300402/ https://www.ncbi.nlm.nih.gov/pubmed/35919231 http://dx.doi.org/10.3332/ecancer.2022.1404 |
Ejemplares similares
-
Fumarate hydratase-deficient renal cell carcinoma: a case report and review of the literature
por: Lv, Yanting, et al.
Publicado: (2023) -
Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma
por: Lindner, Andrea Katharina, et al.
Publicado: (2022) -
Structural basis of fumarate hydratase deficiency
por: Picaud, Sarah, et al.
Publicado: (2011) -
HIF and fumarate hydratase in renal cancer
por: Sudarshan, S, et al.
Publicado: (2007) -
Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study
por: Nikolovski, Ines, et al.
Publicado: (2021)